全文获取类型
收费全文 | 69164篇 |
免费 | 4692篇 |
国内免费 | 2505篇 |
专业分类
耳鼻咽喉 | 308篇 |
儿科学 | 964篇 |
妇产科学 | 1058篇 |
基础医学 | 11779篇 |
口腔科学 | 944篇 |
临床医学 | 3728篇 |
内科学 | 10772篇 |
皮肤病学 | 1061篇 |
神经病学 | 10252篇 |
特种医学 | 835篇 |
外国民族医学 | 19篇 |
外科学 | 4317篇 |
综合类 | 7436篇 |
现状与发展 | 7篇 |
预防医学 | 1681篇 |
眼科学 | 601篇 |
药学 | 12923篇 |
5篇 | |
中国医学 | 1424篇 |
肿瘤学 | 6247篇 |
出版年
2024年 | 119篇 |
2023年 | 828篇 |
2022年 | 1472篇 |
2021年 | 2062篇 |
2020年 | 1782篇 |
2019年 | 1799篇 |
2018年 | 1882篇 |
2017年 | 1894篇 |
2016年 | 1972篇 |
2015年 | 2307篇 |
2014年 | 3802篇 |
2013年 | 5024篇 |
2012年 | 3749篇 |
2011年 | 4373篇 |
2010年 | 3620篇 |
2009年 | 3700篇 |
2008年 | 4008篇 |
2007年 | 3641篇 |
2006年 | 3142篇 |
2005年 | 2707篇 |
2004年 | 2542篇 |
2003年 | 2364篇 |
2002年 | 1887篇 |
2001年 | 1632篇 |
2000年 | 1478篇 |
1999年 | 1306篇 |
1998年 | 1482篇 |
1997年 | 1384篇 |
1996年 | 1251篇 |
1995年 | 989篇 |
1994年 | 907篇 |
1993年 | 812篇 |
1992年 | 608篇 |
1991年 | 565篇 |
1990年 | 416篇 |
1989年 | 355篇 |
1988年 | 299篇 |
1987年 | 276篇 |
1986年 | 294篇 |
1985年 | 341篇 |
1984年 | 279篇 |
1983年 | 170篇 |
1982年 | 236篇 |
1981年 | 186篇 |
1980年 | 136篇 |
1979年 | 81篇 |
1978年 | 55篇 |
1977年 | 44篇 |
1976年 | 34篇 |
1975年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
111.
多巴胺受体的结构和功能 总被引:14,自引:0,他引:14
多巴胺是大脑中含量最丰富的儿茶酚胺类神经递质。多巴胺作为神经递质调控中枢神经系统的多种生理功能。多巴胺系统调节障碍涉及帕金森病,精神分裂症,Tourette综合征,注意力缺陷多动综合征和垂体肿瘤的发生等。本文综述了多巴胺受体的共同特征和各个受体的独特特征,以及它们在中枢神经系统的分布和功能,重点强调了多巴胺受体与学习记忆的关系。 相似文献
112.
重度妊娠高血压综合征患者胎盘表皮生长因子受体的表达 总被引:1,自引:1,他引:0
目的:研究胎盘表皮生长因子受体(EGFR)蛋白及基因的表达在置度妊娠高血压综合征(妊高征)发病中的作用以及对妊高征胎儿生长发育的影响。方法:采用免疫组织化学法和逆转录-聚合酶链反应(RT-PCR)技术测定21例重度妊高征患者[分2组,重度妊高征合并胎儿宫内发育迟缓(IUGR)组9例和重度妊高征未合并IUGR组12例]胎盘EGFR的表达,并与15例正常妊娠者(对照组)比较。结果:与对照组相比,重度妊高征患者胎盘EGFR蛋白及其mRNA的表达显著降低(P<0.01),重度妊高征合并EGFR组与重度妊高征未合并IUGR组之间胎盘EGFR的表达差异无显著性(P>0.05)。结论:胎盘滋养层细胞EGFR表达显著降低,可能是重度妊高征发病的重要因素;如果EGFR的低表达发生较早,容易发生IUGR。 相似文献
113.
TOMOE KINOSHITA KEIICHI HANAKI JUN-ICHI NAGAISHI YUKI KAWASHIMA KAORI ADACHI EIJI NANBA SUSUMU KANZAKI 《Pediatrics international》2007,49(2):133-137
BACKGROUND: Decreased energy expenditure and increased food intake are principal causes for obesity. In the present study, genotypes of beta(3)-adrenergic receptor (beta(3)AR) and of melanocortin-4 receptor (MC4R), both of which are believed to have a close link to the cause of obesity, were analyzed and compared with phenotypes of childhood obesity. METHODS: Thirty-five obese children with moderate to severe obesity were enrolled. Direct sequencing of the MC4R coding region and pinpoint-polymerase chain reaction were used to detect genomic variation in the beta(3)AR gene using peripheral blood-derived DNA. RESULTS: Allele frequency of Trp64Arg variation in the beta(3)AR gene in the obese subjects was 0.16, which is comparable with that in the healthy general population in eastern Asia. Comparison of phenotypical characteristics did not show a significant difference between Trp/Trp and Trp/Arg subjects. It was notable that body height SD was significantly higher in the Trp/Trp than the Trp/Arg subjects (0.93 +/- 1.0 SD vs 0.07 +/- 1.3 SD, P= 0.03). Annual weight gains were far beyond a hypothetical fat gain in an Arg64 heterozygote with decreased energy consumption, suggesting increased food intake in childhood obesity. There was, however, no variation in the MC4R gene despite thorough sequencing of the entire coding region. CONCLUSIONS: The Trp64Arg variation in the beta(3)AR gene has no relationship to the degree or the incidence of childhood obesity. The majority of childhood obesity can be characterized as tall stature, more rapid weight gain than that expected by decreased energy expenditure. Further investigation is necessary in regard to the increased food intake as a major cause of childhood obesity. 相似文献
114.
P. E. Marchiori M. dos Reis M. E. Quevedo M. Scaff W. Cossermelli J. L. Assis R. M. de Oliveira 《Acta neurologica Scandinavica》1989,80(5):387-389
Radioimmunoassay techniques were used to detect antibodies to the acetylcholine receptor (AAChR) in 164 patients with adult-onset myasthenia gravis. AAChR levels above 0.6 nM/l were considered pathological and were found in 67% of the patients with an average value of 58.99 +/- 125.02 nM/l (0.6-900.0). Correlation, with clinical functional status, the histopathological thymus alterations and the different therapeutics used did not disclose any statistically significant differences. 相似文献
115.
116.
重症肌无力患者泼尼松治疗前后免疫学指标的变化 总被引:3,自引:0,他引:3
探讨泼尼松治疗重症肌无力(MG)免疫学机制。对382例MG患者在漏尼松中剂量冲击,小剂量维持疗法治疗前后,检测酰胆碱受体抗炎(AchRab),突触前膜抗体(PsMab),单个核细胞亚群(PBMC),肿瘤坏死因子(TNF),可溶性白介素-2受体(SIL-2R),β2-微球蛋白(β2-m),以及红细胞免疫功能的变化。结果表明:MG患者在泼尼松治疗前后多项免疫指标有显著性的变化。为泼尼松治疗MG提供了评定疗效的免疫学指标,进一步阐明了MG发病的免疫学机制。 相似文献
117.
Objective:This sudy was designed to observe somatostatin receptor subtype 2 (SSTR2) Mrna expression, and investigate the correlations between SSTR2 Mrna expression and steroid receptors in benign and malignant lesions of the breast. Methods: A total of 23 breast carcinomas,16 mammary hyperplasia and 9 mammary adenofibroma samples were analysed. The SSTR2 Mrna expression was examined by in situ hybridization using multiphase oligoprobes.The ER and PR were detected by immunohistochemical staining. A computerized image analysis system was utilized to estimate the relative contents of SSTR2 Mrna. Results: The positive rates of expression (87.0%) and relative contents (0.47) of SSTR2 Mrna in breast cancer were higher than those in benign breast lesions(64%,0.26) respectively( P<0.05). SSTR2 Mrna expression was closely correlated with ER and PR in breast cancer( P<0. 05), A positive correlation between SSTR2 Mrna expression and ER was also found in benign breast lesions. Conclusions: SSTR2 Mrna expressed both in benign and in malignant breast lesions, but higher in malignant than in benign ones. There was a significant positive correlation of SSTR2 Mrna expression with ER or PR. The results suggest that conbined treatment with an antiestrogen and a somatostatin analogue for ER-positive breast cancer is feasible. 相似文献
118.
胆汁胆固醇对胆囊收缩素受体表达的影响 总被引:2,自引:0,他引:2
目的:探讨胆汁胆固醇对胆囊收缩素受体(CCK-R)表达的影响。方法 采用放射免疫分析法和受体放射配基结合法检测对照组、高胆固醇组、自然恢复组及治疗组豚鼠门静脉血CCK水平、胆囊CCK-R的最大结合容量(Bmax)和亲和力(Kd),同时观察空腹胆囊体积(FV)、胆囊胆汁量(FB)和餐后胆囊体积(RV)、胆囊胆汁量(RB)及胆囊收缩率(E%)、胆汁胆固醇浓度的变化。结果 与对照组比较,高胆固醇组豚鼠FV、FB增大(P<0.05),RV、RB也增大,胆囊收缩率下降(P<0.01),胆汁胆固醇浓度升高(P<0.05),门静脉血CCK水平及CCK-R的Kd无改变,而CCK-R的Bmax下降(P<0.01);治疗组上述各项指标正常。结论 胆汁中的高胆固醇通过下调胆囊CCK-R表达而导致胆囊收缩功能障碍,降低胆汁高胆固醇浓度可以促进胆囊动力功能的恢复。 相似文献
119.
Nobuo Takeichi Hisao Ito Rumi Haruta Toshiya Matsuyama Kiyohiko Dohi Eiichi Eiichi 《Cancer science》1991,82(1):19-22
The relationship between the histological grade of dedifferentiation of thyroid cancer and estrogen receptors (ER) was examined immunohistochemically. Thyroid cancers were from postmenopausal females of almost the same mean age (69-73 years old) and within the same period of time (1974–1983). ER immunoreactivity located in the nucleus of the epithelium was found in all 6 well differentiated papillary cancers, and 5 of them (83.3%) showed ER-immunoreactive (ER-IR) cells amounting to 20 or more per visual field (x 100) under a light microscope. Of the 6 cases of poorly differentiated papillary cancer, 5 (83.3%) had 1-19 ER-IR cells per visual field. ER-IR cells were negative in 5 out of 6 cases (83.3%) of anaplastic cancers. Thus, the number of ER-IR cells tended to decrease with the degree of atypism of thyroid cancer (P < 0.001). 相似文献
120.
Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. 总被引:7,自引:0,他引:7
Peter Jacobsen Steen Andersen Kasper Rossing Birgitte V Hansen Hans-Henrik Parving 《Nephrology, dialysis, transplantation》2002,17(6):1019-1024
BACKGROUND: Albuminuria and hypertension are predictors of poor renal and cardiovascular outcome in patients with diabetes. Approximately 30% of type 1 patients with diabetic nephropathy (DN) have albuminuria >1 g/day, and blood pressure >135 and/or >85 mmHg despite antihypertensive therapy with recommended doses of ACE inhibitor (ACEI) and diuretics. We tested the effect of dual blockade of the renin-angiotensin system (RAS) in these patients. METHODS: We performed a randomised double blind crossover trial with 2 months treatment with Irbesartan 300 mg o.d. and placebo added on top of previous antihypertensive treatment. We included 21 type 1 patients with DN responding insufficiently to ACEI and diuretics, as defined above. At the end of each treatment period, albuminuria, 24-h blood pressure and glomerular filtration rate (GFR) were measured. RESULTS: Addition of 300 mg Irbesartan to the patients' usual antihypertensive therapy induced a mean reduction in albuminuria of 37% (95% CI 20-49, P<0.001); from 1574 mg/24 h (95% CI 1162-2132) to 996 mg/24 h (95% CI 699-1419), a reduction in 24-h blood pressure of 8 mmHg systolic (95% CI -2 to 18) and 5 mmHg diastolic (95% CI 1-9) (P=0.11 and 0.01, respectively) (from placebo, mean (SE) 146 (4)/80 (2) mmHg). GFR remained unchanged. Serum potassium increased (mean 4.3 to 4.6 mmol/l, P=0.02). Intervention to reduce serum potassium was needed in two patients with GFR <35 ml/min/1.73 m(2). Otherwise the dual blockade with Irbesartan was safe and well tolerated. CONCLUSIONS: Dual blockade of the RAS may offer additional renal and cardiovascular protection in type 1 patients with DN responding insufficiently to conventional antihypertensive therapy, including recommended doses of ACEI and diuretics. 相似文献